{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:34:08Z","timestamp":1790379248261,"version":"4.1.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Disease","doi-asserted-by":"publisher","award":["R01AI042006"],"award-info":[{"award-number":["R01AI042006"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Disease","doi-asserted-by":"publisher","award":["R01AI093269"],"award-info":[{"award-number":["R01AI093269"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Advancing Clinical Therapeutics Globally","award":["UM1AI068636"],"award-info":[{"award-number":["UM1AI068636"]}]},{"name":"Massachusetts General Hospital Jerome and Celia Reich Endowed Scholar Award"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>People with HIV (PWH) with persistent viremia and adherence challenges to oral antiretroviral therapy (ART) can achieve viral suppression (VS) with long-acting cabotegravir\/rilpivirine (LA-CAB\/RPV). The US guidelines, however, recommend CAB\/RPV only in limited situations. We projected the impact of delaying LA-CAB\/RPV implementation while awaiting trial data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a microsimulation model, we considered 2 approaches for PWH with persistent viremia and intermittent care engagement: daily first-line oral ART or LA-CAB\/RPV, both with intensive-support-services (ISS) to maximize adherence. We evaluated 4 CAB\/RPV implementation scenarios: (1) Current practice (1% on CAB\/RPV); (2) hypothetical Immediate\/Delayed complete implementation (100% CAB\/RPV after 0\u20134\u2005year); (3) 2 Post-trial implementation scenarios: Post-one-arm-trial implementation (1-year trial, 5% uptake\/year thereafter), Post-randomized-trial implementation (3-year trial, 15% uptake\/year thereafter; and (4) Immediate incomplete implementation (1%\u201320% uptake\/year). Outcomes were virologically suppressed person-years (VSPY) and 5-yearmortality. Inputs included cohort size 33,600, initial CD4 count of 150\/\u00b5L, 6-month-VS from observational data: 23% (oral ART), 65% (LA-CAB\/RPV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Current practice projects 35 810 VSPY and 17 640 deaths at 5\u2005years. Immediate complete implementation increases VSPY by 26 830 and averts 3980 deaths; Delayed complete implementation produces 5370 fewer VSPY and 800 more deaths\/delayed year. Post-one-arm-trial implementation yields 1700 more VSPY and 330 fewer deaths than Current practice; Post-randomized-trial implementation yields 1280 more VSPY and 270 fewer deaths. Immediate incomplete implementation at 3% and 2% uptake\/year is similar to Post-one-arm-trial implementation and Post-randomized-trial implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>LA-CAB\/RPV for US PWH with persistent viremia and intermittent care engagement would increase VS and decrease mortality. Increased LA-CAB\/RPV implementation with ISS should be undertaken while awaiting trial results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf428","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T11:56:38Z","timestamp":1754049398000},"page":"e591-e599","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Consequences of Delaying Implementation of Long-Acting Antiretroviral Therapy for People With HIV and Persistent Viremia in the United States"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6095-8494","authenticated-orcid":false,"given":"Pamela P","family":"Pei","sequence":"first","affiliation":[{"name":"Medical Practice Evaluation Center, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2416-5769","authenticated-orcid":false,"given":"Michelle","family":"Jones","sequence":"additional","affiliation":[{"name":"Medical Practice Evaluation Center, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruitian","family":"Hu","sequence":"additional","affiliation":[{"name":"Medical Practice Evaluation Center, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8523-1032","authenticated-orcid":false,"given":"Wanyi","family":"Chen","sequence":"additional","affiliation":[{"name":"Medical Practice Evaluation Center, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E","family":"Sax","sequence":"additional","affiliation":[{"name":"Department of Medicine, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Pandya","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Harvard T. H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6674-5388","authenticated-orcid":false,"given":"Monica","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J","family":"Eron","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of North Carolina at Chapel Hill School of Medicine , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4279-4737","authenticated-orcid":false,"given":"Judith S","family":"Currier","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, David Geffen School of Medicine, University of California , Los Angeles, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9386-9335","authenticated-orcid":false,"given":"Timothy J","family":"Wilkin","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, University of California , San Diego, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna P","family":"Reddy","sequence":"additional","affiliation":[{"name":"Medical Practice Evaluation Center, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Medicine, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Qoshe","sequence":"additional","affiliation":[{"name":"Medical Practice Evaluation Center, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily P","family":"Hyle","sequence":"additional","affiliation":[{"name":"Medical Practice Evaluation Center, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Medicine, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6471-7930","authenticated-orcid":false,"given":"Kenneth A","family":"Freedberg","sequence":"additional","affiliation":[{"name":"Medical Practice Evaluation Center, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Medicine, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Health Policy and Management, Harvard T. H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"2026020907365582300_ciaf428-B1","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"2026020907365582300_ciaf428-B2","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"2026020907365582300_ciaf428-B3","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"2026020907365582300_ciaf428-B4","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48\u2013week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2020","journal-title":"Lancet"},{"key":"2026020907365582300_ciaf428-B5","doi-asserted-by":"crossref","first-page":"ofad500.1422","DOI":"10.1093\/ofid\/ofad500.1422","article-title":"1587. SOLAR 12-month North American results: randomized switch trial of CAB+RPV LA vs. oral BIC\/FTC\/TAF","volume":"10","author":"McKellar","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026020907365582300_ciaf428-B6","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1473-3099(24)00289-5","article-title":"Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial","volume":"24","author":"Kityo","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026020907365582300_ciaf428-B7","author":"US Food and Drug Administration","year":"2021"},{"key":"2026020907365582300_ciaf428-B8","author":"Centers for Disease Control and Prevention","year":"2024"},{"key":"2026020907365582300_ciaf428-B9","doi-asserted-by":"crossref","first-page":"ofy035","DOI":"10.1093\/ofid\/ofy035","article-title":"Degree of housing instability shows independent \u201cdose-response\u201d with virologic suppression rates among people living with human immunodeficiency virus","volume":"5","author":"Clemenzi-Allen","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2026020907365582300_ciaf428-B10","doi-asserted-by":"crossref","first-page":"113092","DOI":"10.1016\/j.socscimed.2020.113092","article-title":"HIV-related stigma and non-adherence to antiretroviral medications among people living with HIV in a rural setting","volume":"258","author":"Kalichman","year":"2020","journal-title":"Soc Sci Med"},{"key":"2026020907365582300_ciaf428-B11","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1007\/s10461-020-03153-0","article-title":"Latent class analysis of syndemic factors associated with sustained viral suppression among Ryan White HIV\/AIDS Program clients in Miami, 2017","volume":"25","author":"Dawit","year":"2021","journal-title":"AIDS Behav"},{"key":"2026020907365582300_ciaf428-B12","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1016\/S2352-3018(23)00051-6","article-title":"Long-acting antiretrovirals and HIV treatment adherence","volume":"10","author":"Nachega","year":"2023","journal-title":"Lancet HIV"},{"key":"2026020907365582300_ciaf428-B13","doi-asserted-by":"crossref","first-page":"ofad500.059","DOI":"10.1093\/ofid\/ofad500.059","article-title":"1028. Real-world use of long-acting cabotegravir + rilpivirine in people with HIV with detectable viral loads at initiation: findings from the OPERA\u00ae Cohort","volume":"10","author":"Hsu","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026020907365582300_ciaf428-B14","doi-asserted-by":"crossref","first-page":"ofad390","DOI":"10.1093\/ofid\/ofad390","article-title":"Projected benefits of long-acting antiretroviral therapy in nonsuppressed people with human immunodeficiency virus experiencing adherence barriers","volume":"10","author":"Chen","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026020907365582300_ciaf428-B15","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1093\/cid\/ciac631","article-title":"First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable human immunodeficiency virus (HIV) viremia in an urban HIV clinic","volume":"76","author":"Christopoulos","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026020907365582300_ciaf428-B16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/cid\/ciad511","article-title":"Long-acting injectable cabotegravir\/rilpivirine effective in a small patient cohort with virologic failure on oral antiretroviral therapy","volume":"78","author":"Brock","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026020907365582300_ciaf428-B17","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/jama.2025.0109","article-title":"HIV viral suppression with use of long-acting antiretroviral therapy in people with and without initial viremia","volume":"333","author":"Spinelli","year":"2025","journal-title":"JAMA"},{"key":"2026020907365582300_ciaf428-B18","author":"Rana","year":"2024"},{"key":"2026020907365582300_ciaf428-B19","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jama.2024.2985","article-title":"Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV from the IAS-USA Guidelines Panel","volume":"331","author":"Sax","year":"2024","journal-title":"JAMA"},{"key":"2026020907365582300_ciaf428-B20","author":"Department of Health and Human Services","year":"2024"},{"key":"2026020907365582300_ciaf428-B21","author":"ViiV Healthcare","year":"2024"},{"key":"2026020907365582300_ciaf428-B22","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/cid\/ciae243","article-title":"Projecting the potential clinical and economic impact of HIV prevention resource reallocation in Tennessee","volume":"79","author":"Borre","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026020907365582300_ciaf428-B23","author":"Kulkarni","year":"2015"},{"key":"2026020907365582300_ciaf428-B24","doi-asserted-by":"crossref","first-page":"ofz537","DOI":"10.1093\/ofid\/ofz537","article-title":"Cost-effectiveness of a medical care coordination program for people with HIV in Los Angeles County","volume":"6","author":"Flash","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2026020907365582300_ciaf428-B25","doi-asserted-by":"crossref","first-page":"ofae125","DOI":"10.1093\/ofid\/ofae125","article-title":"Case series of people with HIV on the long-acting combination of lenacapavir and cabotegravir: call for a trial","volume":"11","author":"Gandhi","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026020907365582300_ciaf428-B26","first-page":"95","article-title":"Virological non-suppression, non-adherence and the associated factors among people living with HIV on dolutegravir-based regimens: a retrospective cohort study","volume":"16","author":"Kabiibi","year":"2024","journal-title":"HIVAIDS (Auckl)"},{"key":"2026020907365582300_ciaf428-B27","author":"Observational Pharmaco-Epidemiology Research & Analysis (OPERA) [Internet]"},{"key":"2026020907365582300_ciaf428-B28","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/infdis\/174.6.1207","article-title":"After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants","volume":"174","author":"Cooper","year":"1996","journal-title":"J Infect Dis"},{"key":"2026020907365582300_ciaf428-B29","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy","volume":"337","author":"Gulick","year":"1997","journal-title":"N Engl J Med"},{"key":"2026020907365582300_ciaf428-B30","author":"National AIDS Treatment Advocacy Project","year":"1998"},{"key":"2026020907365582300_ciaf428-B31","author":"Centers for Disease Control and Prevention","year":"1998"},{"key":"2026020907365582300_ciaf428-B32","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/S2352-3018(23)00047-4","article-title":"Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study","volume":"10","author":"Dorward","year":"2023","journal-title":"Lancet HIV"},{"key":"2026020907365582300_ciaf428-B33","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/cid\/ciae500","article-title":"48-week viral suppression rates in people with HIV starting long-acting CAB\/RPV with initial viremia","volume":"80","author":"Hickey","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026020907365582300_ciaf428-B34","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380\u20131490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2026020907365582300_ciaf428-B35","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"2026020907365582300_ciaf428-B36","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"2026020907365582300_ciaf428-B37","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"2026020907365582300_ciaf428-B38","doi-asserted-by":"crossref","first-page":"e9430","DOI":"10.1097\/MD.0000000000009430","article-title":"Adherence and virologic outcomes among treatment-na\u00efve veteran patients with human immunodeficiency virus type 1 infection","volume":"97","author":"Cheng","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2026020907365582300_ciaf428-B39","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/apc.2014.0165","article-title":"Comparison of HIV virologic failure rates between patients with variable adherence to three antiretroviral regimen types","volume":"29","author":"Gordon","year":"2015","journal-title":"AIDS Patient Care STDs"},{"key":"2026020907365582300_ciaf428-B40","doi-asserted-by":"crossref","first-page":"e0290113","DOI":"10.1371\/journal.pone.0290113","article-title":"The association between all-cause mortality and HIV acquisition risk groups in the United States, 2001\u20132014","volume":"18","author":"Shebl","year":"2023","journal-title":"PLoS One"},{"key":"2026020907365582300_ciaf428-B41","author":"Flexner","year":"2024"},{"key":"2026020907365582300_ciaf428-B42","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.ki.5002354","article-title":"The randomized clinical trial: an unbeatable standard in clinical research?","volume":"72","author":"Stel","year":"2007","journal-title":"Kidney Int"},{"key":"2026020907365582300_ciaf428-B43","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1056\/NEJM200003303421303","article-title":"Viral load and heterosexual transmission of human immunodeficiency virus type 1","volume":"342","author":"Quinn","year":"2000","journal-title":"N Engl J Med"},{"key":"2026020907365582300_ciaf428-B44","author":"US Food and Drug Administration","year":"2023"},{"key":"2026020907365582300_ciaf428-B45","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae631","article-title":"Virologic failure and emergent integrase strand transfer inhibitor drug resistance with long-acting cabotegravir for HIV treatment: a meta-analysis","author":"Perez Navarro","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026020907365582300_ciaf428-B46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/cid\/ciae016","article-title":"Virological failure after switch to long-acting cabotegravir and rilpivirine injectable therapy: an in-depth analysis","volume":"79","author":"Van Welzen","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026020907365582300_ciaf428-B47","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/QAI.0000000000003421","article-title":"Identifying implementation determinants and strategies for long-acting injectable cabotegravir\u2013rilpivirine in people with HIV who are virally unsuppressed","volume":"96","author":"Hickey","year":"2024","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026020907365582300_ciaf428-B48","first-page":"qxaf016","article-title":"State-level variation in access to long-acting injectable antiretroviral therapy for HIV in the United States","volume":"3","author":"Zalla","year":"2025","journal-title":"Health Aff Sch"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf428\/63927791\/ciaf428.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/6\/e591\/63927791\/ciaf428.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/6\/e591\/63927791\/ciaf428.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T12:37:08Z","timestamp":1770640628000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/6\/e591\/8221766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,8,4]]},"published-print":{"date-parts":[[2026,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf428","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,15]]},"published":{"date-parts":[[2025,8,4]]}}}